|
End-of-day quote
Dhaka S.E.
13/09/2026
|
5-day change | 1st Jan Change | ||
| 148.70 BDT | -1.46% |
|
-1.39% | +45.64% |
| 06-27 | Beximco suspension lifted; M1 payment date extension | AN |
| 06-24 | Beximco Pharmaceuticals PLC. Reports Earnings Results for the Third Quarter and Nine Months Ended March 31, 2026 | CI |
| Market Cap | 66.34B 539M 465M 440M 399M 748M 51.54B 752M 5.23B 2.01B 26.22B 2.03B 1.98B 82.85B | P/E 2026 * |
7.66x | P/E 2027 * | 6.96x |
|---|---|---|---|---|---|
| Enterprise Value | 66.34B 539M 465M 440M 399M 748M 51.54B 752M 5.23B 2.01B 26.22B 2.03B 1.98B 82.85B | EV / Sales 2026 * |
1.21x | EV / Sales 2027 * | 1.09x |
| Free-Float |
85.91% | Yield 2026 * |
4.05% | Yield 2027 * | 5.17% |
| 1 day | -1.46% | ||
| 1 week | -1.39% | ||
| Current month | +2.34% | ||
| 1 month | +0.61% | ||
| 3 months | +18.77% | ||
| 6 months | +23.71% | ||
| Current year | +45.64% |
| 1 week | 148 |  | 153.8 |
| 1 month | 141.1 | | 154.5 |
| Current year | 99.5 | | 158.5 |
| 1 year | 99.5 | | 158.5 |
| 3 years | 64.2 | | 158.5 |
| 5 years | 64.2 | | 255.4 |
| 10 years | 47.36 | | 255.4 |
| Manager | Title | Age | Since |
|---|---|---|---|
Iqbal Ahmed
CEO | Chief Executive Officer | - | 04/03/2024 |
| Director of Finance/CFO | 63 | 01/01/2003 | |
| Chief Tech/Sci/R&D Officer | - | - |
| Director | Title | Age | Since |
|---|---|---|---|
| Chairman | - | 19/06/2009 | |
| Director/Board Member | - | 01/02/2010 | |
Iqbal Ahmed
BRD | Director/Board Member | - | 01/01/1985 |
| Change | 5-day change | 1-year change | 3-year change | Capi.($) | ||
|---|---|---|---|---|---|---|
 | -1.46% | -1.39% | +18.20% | +1.71% | 539M | |
| -0.65% | -2.93% | +47.70% | +86.30% | 994B | |
| -0.29% | -3.51% | +49.15% | +61.95% | 640B | |
| +0.83% | +0.26% | +17.76% | +70.10% | 454B | |
| -0.38% | -3.59% | +30.13% | +34.14% | 337B | |
| -0.09% | -13.54% | +13.34% | +24.74% | 261B | |
| -0.43% | -2.48% | -0.73% | +10.64% | 246B | |
| -1.34% | -13.70% | +36.53% | +46.70% | 204B | |
| -3.44% | -7.51% | -20.63% | -58.97% | 190B | |
| -0.75% | -4.82% | +25.46% | +85.90% | 178B | |
| Average | -0.80% | -5.27% | +21.69% | +36.32% | 350.53B | |
| Weighted average by Cap. | -0.51% | -4.42% | +30.96% | +54.64% |
| 2026 * | 2027 * | |
|---|---|---|
| Net sales | 54.78B 445M 384M 363M 329M 618M 42.56B 621M 4.32B 1.66B 21.65B 1.67B 1.64B 68.42B | 60.95B 496M 427M 404M 367M 688M 47.35B 691M 4.8B 1.85B 24.09B 1.86B 1.82B 76.13B |
| Net income | 8.66B 70.44M 60.69M 57.47M 52.09M 97.72M 6.73B 98.21M 683M 262M 3.42B 265M 259M 10.82B | 9.52B 77.45M 66.73M 63.19M 57.27M 107M 7.4B 108M 750M 289M 3.76B 291M 284M 11.9B |
| Net Debt | - | - |
| Date | Price | Change | Volume |
|---|---|---|---|
| 13/09/26 | BDT 148.70 | -1.46% | 733,793 |
| 10/09/26 | BDT 150.90 | -0.13% | 881,413 |
| 09/09/26 | BDT 151.10 | +0.33% | 644,350 |
| 08/09/26 | BDT 150.60 | +0.40% | 1,147,197 |
| 07/09/26 | BDT 150.00 | -0.53% | 1,036,142 |
Trader
This super rating is the result of a weighted average of the rankings based on the following ratings: Valuation (Composite), EPS Revisions (4 months), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Investor
This super composite rating is the result of a weighted average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), EPS Revisions (1 year), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Global
This composite rating is the result of an average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), Financial Estimates Revisions (Composite), Consensus (Composite) and Visibility (Composite). The company must be covered by at least 4 of these 5 ratings for the calculation to be carried out. We recommend that you carefully review the associated descriptions.
Quality
This composite rating is the result of an average of rankings based on the following ratings: Returns (Composite), Profitability (Composite) and Quality of Financial Reporting (Composite), and Financial Health (Composite). The company must be covered by at least 2 of these 3 ratings for the calculation to be performed. We recommend that you carefully read the associated descriptions.
ESG MSCI
The MSCI ESG score assesses a company’s environmental, social, and governance practices relative to its industry peers. Companies are rated from CCC (laggard) to AAA (leader). This rating helps investors incorporate sustainability risks and opportunities into their investment decisions.
Annual profits - Rate of surprise
- Stock Market
- Stocks
- BXPHARMA Stock
Select your edition
All financial news and data tailored to specific country editions
